Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angela Dispenzieri

Showing results (591-600 of 759) with videos related to

Pageof 76
Sort By:
American Journal of Hematology|March 7, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated PatientsGeorge S Mellgard, Abdul-Hamid Bazarbachi, Saurabh Zanwar, et al.
Neurology|May 7, 2026
Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral NeuropathyAlexa H Panrudkevich, Felipe J S Jones, Kamal Shouman, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 76

Showing results (591-600 of 759) with videos related to

Sort By:
Pageof 76
American Journal of Hematology|March 7, 2026
Predicting Early Mortality in Newly Diagnosed AL Amyloidosis: Development and Validation of the PACE Score for Daratumumab-Treated PatientsGeorge S Mellgard, Abdul-Hamid Bazarbachi, Saurabh Zanwar, et al.
Neurology|May 7, 2026
Sensitivity of Nerve and Skin Biopsy and Fat Aspirate for Amyloid in Symptomatic Hereditary ATTR Amyloidosis With Peripheral NeuropathyAlexa H Panrudkevich, Felipe J S Jones, Kamal Shouman, et al.
Amyloid : the International Journal of Experimental and Clinical Investigation : the Official Journal of the International Society of Amyloidosis|December 19, 2022
The impact of Post-Transplant doxycycline in AL amyloidosis - updated results after Long-Term follow upNadine Abdallah, Angela Dispenzieri, Eli Muchtar, et al.
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association|December 3, 2015
The impact of dialysis on the survival of patients with immunoglobulin light chain (AL) amyloidosis undergoing autologous stem cell transplantationNelson Leung, Shaji K Kumar, Siobhan V Glavey, et al.
American Journal of Hematology|December 6, 2018
Peripheral blood biomarkers of early immune reconstitution in newly diagnosed multiple myelomaMoritz Binder, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Neoplasia|June 2, 2025
Improved survival with daratumumab-CyBorD compared with CyBorD as frontline therapy for AL amyloidosisBinoy Yohannan, Matthew Rees, Morie A Gertz, et al.
American Journal of Hematology|June 1, 2010
A Phase II study of (153)Sm-EDTMP and high-dose melphalan as a peripheral blood stem cell conditioning regimen in patients with multiple myelomaAngela Dispenzieri, Gregory A Wiseman, Martha Q Lacy, et al.
Leukemia & Lymphoma|May 18, 2019
Development of thrombocytopenia during first-line treatment and survival outcomes in newly diagnosed multiple myelomaPatrick W Mellors, Moritz Binder, Francis K Buadi, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|August 14, 2013
Trends in utilization and outcomes of autologous transplantation as early therapy for multiple myelomaLuciano J Costa, Mei-Jie Zhang, Xiaobo Zhong, et al.
Blood|April 17, 2012
Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trialShaji K Kumar, Suzanne R Hayman, Francis K Buadi, et al.
Pageof 76